Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119015 | 1.00 | TSHR (0.60) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL2790413 | 0.99 | TSHR (0.62) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL19953531 | 0.99 | TSHR (0.62) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL700153 | 0.87 | TSHR (0.55) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL29282055 | 0.85 | SLC18A2 (0.43) | TSHRNPSR1SLC6A2SLC6A4SLC18A2 | |
| SCHEMBL9526410 | 0.84 | TSHR (0.58) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL11628428 | 0.84 | KDM4E (0.44) | TSHRNPSR1SLC6A2SLC6A4SLC18A2 | |
| SCHEMBL18085727 | 0.84 | TSHR (0.65) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL31569203 | 0.84 | TSHR (0.65) | TSHRNPSR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL3609322 | 0.84 | TSHR (0.65) | TSHRNPSR1SLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9725435-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725435-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368340-A1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003061660-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002059108-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0330467-A1 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | F12, TFPI, F11 | TSHR 3193/4885NPSR1 2000/4885SLC6A2 4436/4885 |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TSHR 3765/4885NPSR1 1962/4885SLC6A2 2781/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | TSHR 3001/4885NPSR1 1024/4885SLC6A2 4361/4885 |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | TSHR 180/4885NPSR1 26/4885SLC6A2 760/4885 |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | TSHR 179/4885NPSR1 27/4885SLC6A2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.